11:32 AM
 | 
Mar 31, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AGS-v: Ph I started

hVIVO said NIH’s National Institute of Allergy and Infectious Disease (NIAID) began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate 2 injections of AGS-v with or without adjuvant given 21 days apart in about 60...

Read the full 157 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >